Trials / Completed
CompletedNCT00635713
Second Line Breast Cancer Trial
A Double-Blind, Randomized, Multi-Center Trial Comparing the Efficacy and Tolerability of 125 and 250mg of Faslodex (Long Acting ICI 182,780) With 1mg Arimidex (Anastrazole) in Postmenopausal Women With Advanced Breast Cancer.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 588 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to compare the effect of 2 doses of FASLODEX with 1 dose of ARIMIDEX in terms of time to tumor progression in postmenopausal women with advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fulvestrant | 125mg |
| DRUG | Anastrozole | ARIMIDEX |
| DRUG | Fulvestrant | 250mg |
Timeline
- Start date
- 1997-05-01
- Completion
- 2004-09-01
- First posted
- 2008-03-14
- Last updated
- 2009-04-10
Source: ClinicalTrials.gov record NCT00635713. Inclusion in this directory is not an endorsement.